Review
Nature Reviews Drug Discovery 7, 143-155 (February 2008) | doi:10.1038/nrd2489
Is raising HDL a futile strategy for atheroprotection?
Tisha Joy1 & Robert A. Hegele1 About the authors
Abstract
The dramatic failure of clinical trials evaluating the cholesterol ester transfer protein inhibitor torcetrapib has led to considerable doubt about the value of raising high-density lipoprotein cholesterol (HDL-C) as a treatment for cardiovascular disease. These results have underscored the intricacy of HDL metabolism, with functional quality perhaps being a more important consideration than the circulating quantity of HDL. As a result, HDL-based therapeutics that maintain or enhance HDL functionality warrant closer investigation. In this article, we review the complexity of HDL metabolism, discuss clinical-trial data for HDL-raising agents, including possible reasons for the failure of torcetrapib, and consider the potential for future HDL-based therapies.
- View At a Glance
Author affiliations
- Robarts Research Institute and Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada, N6A 5K8
Correspondence to: Robert A. Hegele1 Email: hegele@robarts.ca
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Additive effects of statin and dipyridamole on cerebral blood flow and stroke protectionJournal of Cerebral Blood Flow & Metabolism Original Article
See all 26 matches for Research

